HOME >> BIOLOGY >> NEWS
Promising multi-strain HIV vaccine candidate emerges

BALTIMORE, Md.--AIDS researchers have developed a candidate vaccine strategy that, for the first time, demonstrates an ability to elicit antibodies that block the infection of multiple HIV virus strains -- an elusive scientific goal that has been pursued for a decade.

The candidate vaccine - still early in developmental stages at the Institute of Human Virology (IHV) -- is described in a report to appear during the week of Aug. 19-23 in the U.S. Proceedings in the National Academy of Sciences (PNAS). It is authored by Drs. Timothy Fouts, Anthony Devico, and colleagues at the IHV, a center of the University of Maryland Biotechnology Institute and affiliated with the University of Maryland Medical Center, and Dr. Ranajit Pal and colleagues at Advanced BioScience Laboratories, Inc. (ABL) in Kensington, Md.

One of the major challenges in developing an effective AIDS vaccine has long been the fact that the virus that causes AIDS, much like the influenza virus, exists as multiple strains that present many different faces to the immune system, say the authors. The surface of the AIDS virus, HIV, is coated with a protein called gp120 that has chemical features that vary from strain to strain. It has been difficult for researchers to find a single vaccine component that is able to generate antibodies that recognize the many forms of gp120 that exist in nature.

The IHV/ABL research team approached the problem by recognizing that all gp120 molecules have a shared characteristic that allows all HIV strains to bind a molecule on human target cells called CD4. Importantly, once gp120 forms a complex with CD4, it undergoes structural and chemical changes that reveal features shared by all HIV strains.

Taking advantage of this knowledge, the team produced artificial gp120-CD4 complexes that were chemically treated in order to glue or "crosslink" them together. The complexes were then used to generate antibodies in small animals and monkeys.'"/>

Contact: Gwen Fariss Newman
newmang@umbi.umd.edu
410-706-4616
University of Maryland Biotechnology Institute
19-Aug-2002


Page: 1 2 3

Related biology news :

1. Promising hospital anti-infection strategy probably wont work, study shows
2. Promising research: From employment issues to virology
3. Promising new tool shows how dividing cells finish what they start
4. Promising biomarker for melanoma is identified
5. Promising new therapies for deadly form of leukemia
6. Dr. Robert C. Gallo to Collaborate with Visiting Israeli Scientist on Promising HIV Vaccine Research at Marylands Institute of Human Virology
7. SFU Spin-Off Company To Research Promising Antibacterial Agents
8. SFU Molecular Biologist Pursues Promising New Way To Fight Disease
9. UNC-CH Researchers Develop Promising Heart Research Tool
10. Duke Researchers Call Gene Therapy A Promising Strategy For Sickle Cell Anemia
11. Promising Fatty Acid Research Leads To MS Clinical Trial

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Promising multi strain HIV vaccine candidate emerges

(Date:4/15/2014)... LIVERMORE, Calif. Zero-emission hydrogen fuel cell systems soon could ... industrial settings at lower costs and with faster refueling ... Sandia National Laboratories and Hawaii Hydrogen Carriers (HHC). , ... solid-state hydrogen storage system that can refuel at low ... to charge a battery-powered forklift, giving hydrogen a competitive ...
(Date:4/15/2014)... research published in the March/April 2014 issue of ... shows whey protein, either as a supplement combined ... or weight-maintenance diet, may provide men and women benefits ... 14 randomized controlled trials with a total of 626 ... that used whey protein to replace calories in the ...
(Date:4/14/2014)... you,re over 24 years of age you,ve already reached ... according to a new Simon Fraser University study. ... professor Mark Blair, Thompson,s thesis supervisor, and Andrew Henrey, ... news in a just-published PLOS ONE Journal ... science experiments to rest on big data, the trio ...
Breaking Biology News(10 mins):Low-cost, hydrogen-powered forklifts with rapid refueling, zero emissions coming soon 2Low-cost, hydrogen-powered forklifts with rapid refueling, zero emissions coming soon 3Low-cost, hydrogen-powered forklifts with rapid refueling, zero emissions coming soon 4New meta-analysis builds on the power of whey protein for improved body composition 2New meta-analysis builds on the power of whey protein for improved body composition 3Study says we're over the hill at 24 2
(Date:1/15/2014)... 15, 2014 Cynvenio, a cancer diagnostics ... the genomic analysis of tumor cells in the bloodstream, ... web-based cancer decision support application powered by CollabRx, Inc. ... ClearID™ genomic test, Therapy Finder will provide breast cancer ... navigate and understand both the current standard of care ...
(Date:1/15/2014)... IPSWICH, England , January 15, 2014 ... whether technology developed to win races on the Formula ... obesity.  This unique healthcare collaboration between McLaren Applied Technologies ... academics at University Campus Suffolk is being funded by ... inspired by equipment used to collect data about the ...
(Date:1/15/2014)... (PRWEB) January 15, 2014 DTS ... enhancement to its Online Web Portal for Life Science ... have the ability to specify the subject matter of ... 50 life science sub-domains. This will help reduce time-to-delivery ... scientific fields, and decrease the likelihood of error. , ...
(Date:1/15/2014)... 15, 2014 TaiGen Biotechnology Company, Limited ... exclusive agreement with R-Pharm, a leading Russian pharmaceutical ... ) in the Russian Federation ... members of the Commonwealth Independent States (CIS). Nemonoxacin is ... infections including those caused by drug-resistant bacteria. Under ...
Breaking Biology Technology:Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 2Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 4DTS Improves Efficiency for Life Science Document Translations 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4
Cached News: